TY - JOUR T1 - Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios JF - European Respiratory Journal JO - Eur Respir J SP - 25 LP - 29 DO - 10.1183/09031936.00145014 VL - 45 IS - 1 AU - Giovanni Sotgiu AU - Emanuele Pontali AU - Giovanni Battista Migliori Y1 - 2015/01/01 UR - http://erj.ersjournals.com/content/45/1/25.abstract N2 - The figures provided by the World Health Organization (WHO) in its 2013 global tuberculosis (TB) report are remarkable; TB continues to represent a significant clinical and public health problem worldwide [1]. The successes obtained by implementing and scaling-up the WHO public health strategies between 1995 and 2012 (i.e. 22 million lives saved and 56 million patients successfully treated) are outstanding. However, in spite of the dramatic decrease in incidence, prevalence and mortality [1] much needs to be done, and the new WHO post-2015 strategy (which is focused on the concept of TB elimination) is providing further guidance [2–4]. New experimental evidence on anti-TB regimes based on low-efficacious linezolid dosage to treat XDR-TB patients http://ow.ly/C9YpZ ER -